Revolution Medicines (RVMD) Hits All-Time High on Buyout Buzz; Buyer Denies Talks

Core Viewpoint - Revolution Medicines, Inc. experienced a significant stock price surge due to acquisition rumors by AbbVie, which were later denied by AbbVie, leading to volatility in trading [1][3]. Group 1: Stock Performance - Revolution Medicines' stock reached an intra-day high of $105 before closing at $102.71, marking a 28.63% increase from the previous day's near $80 level [2]. - The trading of Revolution Medicines' shares was halted twice due to price volatility during the day [3]. Group 2: Acquisition Rumors - Reports from The Wall Street Journal indicated that AbbVie was in advanced talks to acquire Revolution Medicines for a potential valuation of $20 billion [1][3]. - AbbVie later refuted the acquisition discussions, stating it was "not in discussions with Revolution Medicines" [3]. Group 3: Company Background - Revolution Medicines, founded in 2014, is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [3]. - The company is expected to provide updates on its outlook for 2026 and its pipelines at the upcoming J.P. Morgan Healthcare Conference [4].